Liquidia (LQDA) Stock Price, News & Analysis

Company Overview

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for patients with pulmonary hypertension and other serious cardiopulmonary diseases. The company is headquartered in Research Triangle Park, North Carolina, and uses its proprietary PRINT technology to engineer drug particles with controlled size, shape and composition for inhaled and injectable medicines.

Liquidia’s lead product is Yutrepia (treprostinil) inhalation powder, a dry-powder formulation of treprostinil delivered through a proprietary inhaler. The U.S. Food and Drug Administration approved Yutrepia for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease in adults. The product is intended to provide a convenient inhaled treatment option designed to improve exercise ability and reduce disease progression.

The company also maintains a pipeline of additional therapies based on treprostinil and its PRINT technology, including investigational formulations intended to address unmet needs in pulmonary vascular disease. Liquidia was founded in 2004 and became a publicly traded company in 2018. Its activities primarily serve patients and healthcare providers in the United States, with potential international opportunities dependent on future regulatory approvals and commercialization arrangements.

Key Stats

• Today's Range: $38.69 to $42.83
• 50-Day Range: $25.91 to $77.70
• 52-Week Range: $22.05 to $93.61
• Volume: 3.80 million shs
• Average Volume: 7.25 million shs
• Market Capitalization: $3.82 billion
• P/E Ratio: 31.13
• Dividend Yield: N/A
• Price Target: $72.85
• Consensus Rating: Hold

Liquidia Stock Analysis - MarketRank™

Liquidia scored higher than 93% of companies evaluated by MarketBeat, and ranked 23rd out of 902 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Hold

Consensus Rating

Liquidia has received a consensus rating of Hold. The company's average rating score is 2.42, and is based on 1 strong buy rating, 5 buy ratings, 4 hold ratings, and 2 sell ratings.

Upside Potential

Liquidia has a consensus price target of $72.85, representing about 70.8% upside from its current price of $42.65.

Amount of Analyst Coverage

Liquidia has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 3.90%

Earnings Growth

Earnings for Liquidia are expected to grow by 3.90% in the coming year, from $2.05 to $2.13 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Liquidia is 31.13, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.35.

Price to Earnings Ratio vs. Sector

The P/E ratio of Liquidia is 31.13, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 271.05.

Price to Earnings Growth Ratio

Liquidia has a PEG Ratio of 0.37. PEG Ratios below 1 indicate that a company could be undervalued.

Price to Book Value per Share Ratio

Liquidia has a P/B Ratio of 83.63. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

18.98% of the float of Liquidia has been sold short.

Short Interest Ratio / Days to Cover

Liquidia has a short interest ratio ("days to cover") of 3.84, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Liquidia has recently increased by 2.12%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Liquidia does not currently pay a dividend.

Dividend Growth

Liquidia does not have a long track record of dividend growth.

News and Social Media

• Score: 3.5 / 5
• News Sentiment: 0.68

News Sentiment

Liquidia has a news sentiment score of 0.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Liquidia this week, compared to 9 articles on an average week.

Search Interest

28 people have searched for LQDA on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.

MarketBeat Follows

7 people have added Liquidia to their MarketBeat watchlist in the last 30 days. This is an increase of 133% compared to the previous 30 days.

Company Ownership

• Score: 2.1 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Liquidia insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $25,848,390.00 in company stock.

Percentage Held by Insiders

25.60% of the stock of Liquidia is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

64.54% of the stock of Liquidia is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/12/2026
• Today: 10/25/2026
• Next Earnings (Estimated): 11/02/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:LQDA
• CIK: 1819576
• Web: www.liquidia.com
• Phone: (919) 328-4400
• Fax: N/A
• Employees: 216
• Year Founded: 2004

Price Target and Rating

• Average Price Target for Liquidia: $72.85
• High Price Target: $130.00
• Low Price Target: $33.00
• Potential Upside/Downside: +70.8%
• Consensus Rating: Hold
• Rating Score (0-4): 2.42
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): $1.37
• Trailing P/E Ratio: 31.13
• Forward P/E Ratio: 20.80
• P/E Growth: 0.37
• Net Income: -$68.92 million
• Net Margins: 30.74%
• Pretax Margin: 33.16%
• Return on Equity: 149.65%
• Return on Assets: 36.30%

Debt

• Debt-to-Equity Ratio: 0.63
• Current Ratio: 2.31
• Quick Ratio: 2.12

Sales & Book Value

• Annual Sales: $158.32 million
• Price / Sales: 24.11
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.51 per share
• Price / Book: 83.63

Miscellaneous

• Outstanding Shares: 89,510,000
• Free Float: 66,595,000
• Market Cap: $3.82 billion
• Optionable: Optionable
• Beta: 0.61